Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.41 |
| ▸ | ESR1 | P03372 | 5/20 | 0.41 |
| ▸ | ESRRB | O95718 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949489 | 0.84 | HPGDS (0.47) | MAP4K4CDK8CLK2CDK7CDK9 | |
| SCHEMBL28806465 | 0.80 | PARP1 (0.41) | ALDH1A1PARP1PDGFRBPDGFRA | |
| SCHEMBL535363 | 0.78 | ALDH1A1 (0.41) | MAP4K4CDK8CLK2CDK7CDK9 | |
| SCHEMBL444107 | 0.77 | ALDH1A1 (0.62) | ALDH1A1PARP1PDGFRBPDGFRA | |
| SCHEMBL27856310 | 0.74 | HDAC8 (0.43) | MAP4K4CDK8CLK2CDK7CDK9 | |
| SCHEMBL2474536 | 0.74 | CYP1A2 (0.50) | ESR2ESR1 | |
| SCHEMBL29624584 | 0.74 | CYP1A2 (0.50) | ESR2ESR1 | |
| SCHEMBL1360422 | 0.73 | MAP4K4 (0.46) | MAP4K4CDK8CLK2CDK7CDK9 | |
| SCHEMBL16289378 | 0.73 | MAP4K4 (0.46) | MAP4K4CDK8CLK2CDK7CDK9 | |
| SCHEMBL1359776 | 0.73 | MAP4K4 (0.46) | MAP4K4CDK8CLK2CDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507509-B2 | Saturated and insaturated bi- or tricyclic aryloxyacetamine derivatives and their use as fungicides | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-13 | — | — | US | disclosed |
| CN-101827817-B | Saturated and insaturated bi- or tricyclic aryloxyacetamide derivatives and their use as fungicides | SYNGENTA CROP PROTECTION LLC | 2013-05-08 | — | — | CN | disclosed |
| EP-2185518-B1 | Aryloxyacetamide derivatives and their use as fungicides | SYNGENTA PARTICIPATIONS AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| CN-101827817-A | Saturated and undersaturated two-or three cyclophane oxygen yl acetamide derivatives and they as the purposes of mycocide | SYNGENTA PARTICIPATIONS AGSYNGENTA PARTICIPATIONS AG | 2010-09-08 | — | — | CN | disclosed |
| EP-2185518-A2 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | Syngenta Participations AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009030467-A2 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG, (CH) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298356-A1 | SATURATED AND INSATURATED BI- OR TRICYCLIC ARYLOXYACETAMINE DERIVATIVES AND THEIR USE AS FUNGICIDES | CYP1A2, CYP1B1, CYP1A1 | MAP4K4 3458/4885CDK8 2670/4885CLK2 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.